Broad interest in Merck KGaA's generic-drug unit reflects the consolidation of the once-fragmented generics industry and the ambitions of growing Indian firms to expand overseas.
Several bidders have submitted first-round offers for the business, offering from $5 billion to $6.5 billion, according to people familiar with the matter.
Generic-drug makers Teva Pharmaceutical Industries Ltd., of Israel; Mylan Laboratories Inc., of Canonsburg, Pa.; Actavis Group HF, of Iceland; and Ranbaxy Laboratories Ltd., of India, submitted bids by the Monday deadline, a person familiar with the matter said. Ranbaxy officials confirmed yesterday that the company had bid. Private-equity firms Bain Capital LLC and Apax Partners LP also made a joint offer for the Merck unit, people familiar with the matter said.
More at WSJ (free today!)
No comments:
Post a Comment